Douglas J. Swirsky
Mr. Swirsky is President and Chief Executive Officer of publicly traded Rexahn Pharmaceuticals, Inc. In addition to his roles at Rexahn, Mr. Swirsky is currently Chairman of the Board of Cellectar Biosciences, Inc., a publicly traded, clinical stage biopharmaceutical company. He has more than two decades of relevant experience in the biopharmaceutical and healthcare sectors, having served as a director of, or in senior management positions at, a number of publicly held companies over the last 14 years and having provided counsel to corporate clients as a healthcare investment banker. Prior to joining Rexahn in January 2018, from 2013 through its sale to Precigen, Inc. (formerly known as Intrexon Corporation) in 2017, Mr. Swirsky was President and Chief Executive Officer of publicly traded biotechnology company, GenVec, Inc., which he joined in 2006 as Chief Financial Officer. Prior to joining GenVec, Mr. Swirsky worked at Stifel Nicolaus, where he served as a managing director and the head of Life Sciences Investment Banking. Previously, Mr. Swirsky held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason.
Mr. Swirsky is a certified public accountant and a CFA® charterholder. He earned a B.S. in Business Administration from Boston University and an M.B.A. from the Kellogg School of Management at Northwestern University.